Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma - a short report
- 7 December 2017
- journal article
- research article
- Published by Springer Nature in Cellular Oncology
- Vol. 41 (2) , 213-221
Abstract
Purpose Glioblastoma (GBM) ranks among the most challenging cancers to treat and there is an urgent need for clinically relevant prognostic and diagnostic biomarkers. Here, we set out to investigate the expression of eight proteins (bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1) in GBM with the specific aim to establish immunohistochemistry cut-off points with clinical relevance. Methods Immunohistochemistry (IHC) was used to examine protein expression in 55 surgical GBM specimens using H-scores, and IHC cut-off points were established using the Cutoff Finder web platform. Protein co-expression and its correlation with histopathological features were assessed, and cases were classified according to IDH1 mutation status. Survival curves were determined using Kaplan-Meier analyses. Results Clinical and molecular parameters found to be correlated with overall survival (OS) were tumor size (r = −0.278; p = 0.048), p53 (r = −0.452; p = 0.001), p16 (r = 0.351; p = 0.012) and Sox11 (r = 0.324; p = 0.020). In addition, we found that tumor size correlated with cyclin D1 (r = −0.282; p = 0.037), p53 (r = 0.269; p = 0.041), Sox11 (r = −0.309; p = 0.022) and WT1 (r = −0.372; p = 0.003). Variables found to be significantly associated with IDH1 mutation status were OS (p < 0.01), age (p < 0.01), cyclin D1 (p = 0.046), p16 (p = 0.019) and Sox11 (p = 0.012). Variables found to be significantly associated with a poor survival were tumor size >5 cm (p < 0.001), bcl-2 score > 40 (p = 0.034), cyclin D1 score ≤ 70 (p = 0.004), p16 score ≤ 130 (p = 0.005), p53 score > 20 (p = 0.003), Sox11 score ≤ 40 (p < 0.001) and WT1 score ≤ 270 (p = 0.02). Conclusions Correlations between protein biomarkers and main clinical GBM variables were identified. The establishment of distinct biomarker cut-off points may enable clinicians and pathologists to better weigh their prognostic value.Keywords
This publication has 39 references indexed in Scilit:
- Cancer heterogeneity: implications for targeted therapeuticsBritish Journal of Cancer, 2013
- Cyclins and Cell Cycle Control in Cancer and DiseaseGenes & Cancer, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumorsOncogene, 2011
- Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patientsBrain Tumor Pathology, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in GliomasJournal of Clinical Oncology, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic inventionMolecular Cancer, 2007
- Epidemiology and etiology of gliomasActa Neuropathologica, 2005